Investment, Funding & Disinvestments

The collaboration combines Weave Bio’s artificial intelligence tools with Takeda’s regulatory expertise to simplify and speed up activities involved in preparing submissions and responding to questions from health authorities.

The initiative forms part of ADCAN Pharma’s efforts to strengthen the UAE’s capacity to produce complex and specialised medicines domestically.

The platform has grown to serve about 70,000 members across more than 400 companies and connects users with more than 1,200 pharmacies and healthcare providers in the two countries.

AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.

Amyl Therapeutics will expand its laboratory facilities at the LegiaPark life sciences campus in Liège, Belgium, to accommodate its growing research programme.

The acquisition will give Lilly access to Merida’s technology for developing biologics that selectively eliminate disease-causing autoantibodies.

Under the agreement, Teva would acquire worldwide rights to Igalmi (dexmedetomidine) sublingual film, a prescription medicine, as well as BXCL501, an investigational therapy.

The new site will complement RayzeBio’s existing 77,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, located about 20 miles southwest of Whitestown.

These therapies can require multiple stages, including DNA starting materials, RNA production, targeted delivery technologies, formulation, analytical testing and scalable drug product manufacturing.

The two firms launched Metsera in 2022, and the biotech emerged from stealth in 2024 after securing US$290 million in financing.